ID   GIT1_RAT                Reviewed;         770 AA.
AC   Q9Z272;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   02-OCT-2024, entry version 181.
DE   RecName: Full=ARF GTPase-activating protein GIT1;
DE            Short=ARF GAP GIT1;
DE   AltName: Full=Cool-associated and tyrosine-phosphorylated protein 1;
DE            Short=CAT-1;
DE            Short=CAT1;
DE   AltName: Full=G protein-coupled receptor kinase-interactor 1;
DE   AltName: Full=GRK-interacting protein 1;
DE   AltName: Full=GRK-interactor 1 {ECO:0000303|PubMed:9826657};
GN   Name=Git1 {ECO:0000303|PubMed:9826657};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH GRK2; GRK3; GRK5 AND
RP   GRK6, TISSUE SPECIFICITY, AND CHARACTERIZATION.
RX   PubMed=9826657; DOI=10.1073/pnas.95.24.14082;
RA   Premont R.T., Claing A., Vitale N., Freeman J.L.R., Pitcher J.A.,
RA   Patton W.A., Moss J., Vaughan M., Lefkowitz R.J.;
RT   "Beta2-adrenergic receptor regulation by GIT1, a G protein-coupled receptor
RT   kinase-associated ADP ribosylation factor GTPase-activating protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14082-14087(1998).
RN   [2]
RP   FUNCTION, INTERACTION WITH ARHGEF7; PXN AND PTK2, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=10938112; DOI=10.1128/mcb.20.17.6354-6363.2000;
RA   Zhao Z.-S., Manser E., Loo T.-H., Lim L.;
RT   "Coupling of PAK-interacting exchange factor PIX to GIT1 promotes focal
RT   complex disassembly.";
RL   Mol. Cell. Biol. 20:6354-6363(2000).
RN   [3]
RP   INTERACTION WITH PXN AND TGFB1I1.
RX   PubMed=12153727; DOI=10.1093/oxfordjournals.jbchem.a003222;
RA   Nishiya N., Shirai T., Suzuki W., Nose K.;
RT   "Hic-5 interacts with GIT1 with a different binding mode from paxillin.";
RL   J. Biochem. 132:279-289(2002).
RN   [4]
RP   FUNCTION, INTERACTION WITH ARHGEF7; PCLO; GIT2; GRIP1; PPFIA1; PTK2 AND
RP   PXN, HOMOOLIGOMERIZATION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DOMAIN,
RP   AND MUTAGENESIS OF PHE-285; LEU-288; ARG-298; ARG-299 AND 432-LEU--PRO-483.
RX   PubMed=12473661; DOI=10.1074/jbc.m212287200;
RA   Kim S., Ko J., Shin H., Lee J.R., Lim C., Han J.H., Altrock W.D.,
RA   Garner C.C., Gundelfinger E.D., Premont R.T., Kaang B.K., Kim E.;
RT   "The GIT family of proteins forms multimers and associates with the
RT   presynaptic cytomatrix protein Piccolo.";
RL   J. Biol. Chem. 278:6291-6300(2003).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12695502; DOI=10.1083/jcb.200211002;
RA   Zhang H., Webb D.J., Asmussen H., Horwitz A.F.;
RT   "Synapse formation is regulated by the signaling adaptor GIT1.";
RL   J. Cell Biol. 161:131-142(2003).
RN   [6]
RP   FUNCTION, INTERACTION WITH ARHGEF7; GRIA2/3; GRIP1; PPFIA1; PPFIA2; PPFIA4;
RP   PTK2; PTK2B AND PXN, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=12629171; DOI=10.1523/jneurosci.23-05-01667.2003;
RA   Ko J., Kim S., Valtschanoff J.G., Shin H., Lee J.R., Sheng M.,
RA   Premont R.T., Weinberg R.J., Kim E.;
RT   "Interaction between liprin-alpha and GIT1 is required for AMPA receptor
RT   targeting.";
RL   J. Neurosci. 23:1667-1677(2003).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH MAPK1 AND MAPK3.
RX   PubMed=15923189; DOI=10.1074/jbc.m502271200;
RA   Yin G., Zheng Q., Yan C., Berk B.C.;
RT   "GIT1 is a scaffold for ERK1/2 activation in focal adhesions.";
RL   J. Biol. Chem. 280:27705-27712(2005).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15800193; DOI=10.1523/jneurosci.3553-04.2005;
RA   Zhang H., Webb D.J., Asmussen H., Niu S., Horwitz A.F.;
RT   "A GIT1/PIX/Rac/PAK signaling module regulates spine morphogenesis and
RT   synapse formation through MLC.";
RL   J. Neurosci. 25:3379-3388(2005).
RN   [9]
RP   FUNCTION, INTERACTION WITH ARHGEF7; EFNB1 AND NCK2, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, PHOSPHORYLATION AT TYR-392, AND MUTAGENESIS OF TYR-392.
RX   PubMed=17310244; DOI=10.1038/nn1858;
RA   Segura I., Essmann C.L., Weinges S., Acker-Palmer A.;
RT   "Grb4 and GIT1 transduce ephrinB reverse signals modulating spine
RT   morphogenesis and synapse formation.";
RL   Nat. Neurosci. 10:301-310(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-371; SER-384; SER-397;
RP   THR-401; SER-419; SER-570; SER-580; SER-601 AND SER-639, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [11]
RP   FUNCTION, INTERACTION WITH ARHGEF7 AND GRIN3A, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=24297929; DOI=10.1073/pnas.1312211110;
RA   Fiuza M., Gonzalez-Gonzalez I., Perez-Otano I.;
RT   "GluN3A expression restricts spine maturation via inhibition of GIT1/Rac1
RT   signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:20807-20812(2013).
RN   [12]
RP   FUNCTION, INTERACTION WITH GABRB3 AND GABRG2, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=25284783; DOI=10.1016/j.celrep.2014.08.061;
RA   Smith K.R., Davenport E.C., Wei J., Li X., Pathania M., Vaccaro V., Yan Z.,
RA   Kittler J.T.;
RT   "GIT1 and betaPIX are essential for GABA(A) receptor synaptic stability and
RT   inhibitory neurotransmission.";
RL   Cell Rep. 9:298-310(2014).
RN   [13]
RP   FUNCTION.
RX   PubMed=25009255; DOI=10.1523/jneurosci.5183-13.2014;
RA   Kehoe L.A., Bellone C., De Roo M., Zandueta A., Dey P.N., Perez-Otano I.,
RA   Muller D.;
RT   "GluN3A promotes dendritic spine pruning and destabilization during
RT   postnatal development.";
RL   J. Neurosci. 34:9213-9221(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 426-483, DIMERIZATION,
RP   INTERACTION WITH ARHGEF7, AND DOMAIN.
RX   PubMed=19136011; DOI=10.1016/j.jmb.2008.12.050;
RA   Schlenker O., Rittinger K.;
RT   "Structures of dimeric GIT1 and trimeric beta-PIX and implications for GIT-
RT   PIX complex assembly.";
RL   J. Mol. Biol. 386:280-289(2009).
CC   -!- FUNCTION: GTPase-activating protein for ADP ribosylation factor family
CC       members, including ARF1 (PubMed:9826657). Multidomain scaffold protein
CC       that interacts with numerous proteins and therefore participates in
CC       many cellular functions, including receptor internalization, focal
CC       adhesion remodeling, and signaling by both G protein-coupled receptors
CC       and tyrosine kinase receptors (PubMed:9826657). Through PAK1
CC       activation, positively regulates microtubule nucleation during
CC       interphase. Plays a role in the regulation of cytokinesis; for this
CC       function, may act in a pathway also involving ENTR1 and PTPN13 (By
CC       similarity). May promote cell motility both by regulating focal complex
CC       dynamics and by the activation of RAC1 (PubMed:10938112). May act as
CC       scaffold for MAPK1/3 signal transduction, recruiting MAPK1/3 to focal
CC       adhesions after EGF stimulation via a Src-dependent pathway, hence
CC       stimulating cell migration (PubMed:15923189). Plays a role in brain
CC       development and function. Involved in the regulation of spine density
CC       and synaptic plasticity that is required for processes involved in
CC       learning (By similarity). Plays an important role in dendritic spine
CC       morphogenesis and synapse formation (PubMed:12695502, PubMed:15800193,
CC       PubMed:17310244, PubMed:24297929, PubMed:25009255). In hippocampal
CC       neurons, recruits guanine nucleotide exchange factors (GEFs), such as
CC       ARHGEF7/beta-PIX, to the synaptic membrane. These in turn locally
CC       activate RAC1, which is an essential step for spine morphogenesis and
CC       synapse formation (PubMed:12473661). May contribute to the organization
CC       of presynaptic active zones through oligomerization and formation of a
CC       Piccolo/PCLO-based protein network, which includes ARHGEF7/beta-PIX and
CC       FAK1 (PubMed:12473661). In neurons, through its interaction with
CC       liprin-alpha family members, may be required for AMPA receptor
CC       (GRIA2/3) proper targeting to the cell membrane (PubMed:12629171). In
CC       complex with GABA(A) receptors and ARHGEF7, plays a crucial role in
CC       regulating GABA(A) receptor synaptic stability, maintaining
CC       GPHN/gephyrin scaffolds and hence GABAergic inhibitory synaptic
CC       transmission, by locally coordinating RAC1 and PAK1 downstream effector
CC       activity, leading to F-actin stabilization (PubMed:25284783). May also
CC       be important for RAC1 downstream signaling pathway through PAK3 and
CC       regulation of neuronal inhibitory transmission at presynaptic input (By
CC       similarity). Required for successful bone regeneration during fracture
CC       healing. The function in intramembranous ossification may, at least
CC       partly, exerted by macrophages in which GIT1 is a key negative
CC       regulator of redox homeostasis, IL1B production, and glycolysis, acting
CC       through the ERK1/2/NRF2/NFE2L2 axis (By similarity). May also play a
CC       role in angiogenesis during fracture healing (By similarity). In this
CC       process, may regulate activation of the canonical NF-kappa-B signal in
CC       bone mesenchymal stem cells by enhancing the interaction between NEMO
CC       and 'Lys-63'-ubiquitinated RIPK1/RIP1, eventually leading to enhanced
CC       production of VEGFA and others angiogenic factors (By similarity).
CC       Essential for VEGF signaling through the activation of phospholipase C-
CC       gamma and ERK1/2, hence may control endothelial cell proliferation and
CC       angiogenesis (By similarity). {ECO:0000250|UniProtKB:Q68FF6,
CC       ECO:0000250|UniProtKB:Q9Y2X7, ECO:0000269|PubMed:10938112,
CC       ECO:0000269|PubMed:12473661, ECO:0000269|PubMed:12629171,
CC       ECO:0000269|PubMed:12695502, ECO:0000269|PubMed:15800193,
CC       ECO:0000269|PubMed:15923189, ECO:0000269|PubMed:17310244,
CC       ECO:0000269|PubMed:24297929, ECO:0000269|PubMed:25009255,
CC       ECO:0000269|PubMed:25284783, ECO:0000269|PubMed:9826657}.
CC   -!- SUBUNIT: Forms homodimers and possibly oligomers (PubMed:12473661,
CC       PubMed:19136011). May form heterooligomers with GIT2 (Probable).
CC       Interacts with G protein-coupled receptor kinases, including GRK2,
CC       GRK3, GRK5 and GRK6 (PubMed:9826657). Interacts with PPFIA1, PPFIA2 and
CC       PPFIA4 (PubMed:12473661, PubMed:12629171). Interacts with GRIP1 and
CC       forms a ternary complex with PPFIA1 and GRIP1 (PubMed:12473661,
CC       PubMed:12629171). Directly interacts with ARHGEF7/beta-PIX, forming in
CC       vitro a heptameric complex made of a GIT1 dimer and an ARHGEF7 trimer
CC       (PubMed:10938112, PubMed:12473661, PubMed:12629171, PubMed:17310244,
CC       PubMed:19136011). Directly interacts with PXN/paxillin; this
CC       interaction is enhanced in the presence of ARHGEF7 (PubMed:10938112,
CC       PubMed:12153727, PubMed:12473661, PubMed:12629171). Directly interacts
CC       (via C-terminus) with TGFB1I1/Hic-5 (via LD motif 3) (PubMed:12153727).
CC       Directly interacts with PTK2/FAK1 (PubMed:10938112, PubMed:12473661,
CC       PubMed:12629171). May interact with PTK2B/PYK2; this interaction may be
CC       indirect (PubMed:12629171). Interacts with AMPA receptors GRIA2/3
CC       (PubMed:12629171). Directly interacts with protein Piccolo/PCLO
CC       (PubMed:12473661). Forms a complex with Ephrin-B1/EFNB1 and NCK2/GRB4
CC       (via SH2); this interaction is important for spine morphogenesis and
CC       synapse formation. Interaction with NCK2 is transient and depends upon
CC       GIT1 phosphorylation at Tyr-392 (PubMed:17310244). Interacts with
CC       GRIN3A/GluN3A (via C-terminus); this interaction competes with GIT1
CC       interaction with ARHGEF7 and limits synaptic localization of GIT1
CC       (PubMed:24297929). Interacts with IKBKG/NEMO in resting bone
CC       mesenchymal stem cells, as well as in TNF-stimulated cells; this
CC       interaction may increase IKBKG affinity for 'Lys-63'-linked
CC       polyubiquitin chains (By similarity). Interacts with GABA(A) receptors,
CC       including GABRB3 and GABRG2 (PubMed:25284783). Interacts with SCRIB (By
CC       similarity). Interacts (via N- and C-terminus) with ENTR1/SDCCAG3 (via
CC       N-terminus); this interaction is direct. May form a tripartite complex
CC       with ENTR1 and PTPN13 (By similarity). Interacts with YWHAZ (By
CC       similarity). Interacts with PAK1 and PAK3 (By similarity). Directly
CC       interacts (via N-terminus) with gamma-tubulin (By similarity).
CC       Interacts with MAPK1 and MAPK3; this interaction is required for
CC       MAPK1/3 recruitment to focal adhesions (PubMed:15923189).
CC       {ECO:0000250|UniProtKB:Q68FF6, ECO:0000250|UniProtKB:Q9Y2X7,
CC       ECO:0000269|PubMed:10938112, ECO:0000269|PubMed:12153727,
CC       ECO:0000269|PubMed:12473661, ECO:0000269|PubMed:12629171,
CC       ECO:0000269|PubMed:15923189, ECO:0000269|PubMed:17310244,
CC       ECO:0000269|PubMed:19136011, ECO:0000269|PubMed:24297929,
CC       ECO:0000269|PubMed:25284783, ECO:0000269|PubMed:9826657,
CC       ECO:0000305|PubMed:12473661}.
CC   -!- INTERACTION:
CC       Q9Z272; Q9ES28: Arhgef7; Xeno; NbExp=2; IntAct=EBI-3842379, EBI-642580;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9Y2X7}. Synapse
CC       {ECO:0000269|PubMed:17310244, ECO:0000269|PubMed:25284783}. Presynapse
CC       {ECO:0000269|PubMed:12473661, ECO:0000269|PubMed:12629171,
CC       ECO:0000269|PubMed:12695502}. Postsynapse {ECO:0000269|PubMed:12629171,
CC       ECO:0000269|PubMed:12695502}. Postsynaptic density
CC       {ECO:0000269|PubMed:12629171}. Cell junction, focal adhesion
CC       {ECO:0000305|PubMed:10938112}. Cell projection, lamellipodium
CC       {ECO:0000250|UniProtKB:Q9Y2X7}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250|UniProtKB:Q9Y2X7}.
CC       Cytoplasm, cytoskeleton, spindle pole {ECO:0000250|UniProtKB:Q9Y2X7}.
CC       Note=Cycles between at least 3 distinct intracellular compartments,
CC       including focal adhesions, cytosolic complexes, containing at least
CC       PXN/paxillin, ARHGEF7 and PAK1, and membrane protrusions. During cell
CC       migration, moves from the disassembling adhesions into the cytosol and
CC       towards the leading edge. In adherent cells, localizes to adhesions.
CC       Recruitment to adhesions may be mediated by RAC1 and active tyrosine-
CC       phosphorylated PXN (By similarity). May be present in both excitatory,
CC       as well as inhibitory synapses (PubMed:12695502, PubMed:25284783). In
CC       hippocampal neurons, recruitment of GIT1 to synapses is regulated by
CC       ephrinB activation and ephrinB downstream effector GRB4/NCK2
CC       (PubMed:17310244). In hippocampal neurons, partially colocalizes with
CC       PCLO (PubMed:12473661). Interaction with GRIN3A limits GIT1 synaptic
CC       localization (PubMed:24297929). Localization to the centrosome does not
CC       depend upon the presence of gamma-tubulin (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Y2X7, ECO:0000269|PubMed:12473661,
CC       ECO:0000269|PubMed:12695502, ECO:0000269|PubMed:17310244,
CC       ECO:0000269|PubMed:24297929, ECO:0000269|PubMed:25284783}.
CC   -!- TISSUE SPECIFICITY: Widely expressed (PubMed:9826657). Expressed at
CC       high levels in testis (at protein level) (PubMed:10938112). Expressed
CC       in the brain, including in CA1 hippocampal neurons, in the amygdala,
CC       and thalamic nuclei (at protein level) (PubMed:10938112,
CC       PubMed:12473661, PubMed:12629171, PubMed:12695502, PubMed:15800193,
CC       PubMed:17310244, PubMed:24297929, PubMed:25284783).
CC       {ECO:0000269|PubMed:10938112, ECO:0000269|PubMed:12473661,
CC       ECO:0000269|PubMed:12629171, ECO:0000269|PubMed:12695502,
CC       ECO:0000269|PubMed:15800193, ECO:0000269|PubMed:17310244,
CC       ECO:0000269|PubMed:24297929, ECO:0000269|PubMed:25284783,
CC       ECO:0000269|PubMed:9826657}.
CC   -!- DEVELOPMENTAL STAGE: In the brain cortex and in the hippocampus,
CC       continuously expressed from P0 to adult age (at protein level).
CC       {ECO:0000269|PubMed:24297929}.
CC   -!- DOMAIN: The coiled coil region mediates dimerization.
CC       {ECO:0000269|PubMed:12473661, ECO:0000269|PubMed:19136011}.
CC   -!- PTM: Phosphorylated on tyrosine residues by PTK2/FAK1 and SRC in
CC       growing fibroblasts (PubMed:10938112). Phosphorylation at Tyr-392 is
CC       induced by activation of Ephrin-B1/EFNB1 and catalyzed by SRC family
CC       kinases. It is required for the interaction with NCK2 and for GIT1
CC       recruitment to synapses in hippocampal neurons (PubMed:17310244).
CC       {ECO:0000269|PubMed:10938112, ECO:0000269|PubMed:17310244}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF085693; AAC83348.1; -; mRNA.
DR   RefSeq; NP_114002.1; NM_031814.1.
DR   PDB; 2JX0; NMR; -; A=640-770.
DR   PDB; 2W6A; X-ray; 1.40 A; A/B=426-483.
DR   PDB; 6IUH; X-ray; 1.80 A; A/B=645-770.
DR   PDB; 6IUI; X-ray; 2.60 A; A/B=645-770.
DR   PDBsum; 2JX0; -.
DR   PDBsum; 2W6A; -.
DR   PDBsum; 6IUH; -.
DR   PDBsum; 6IUI; -.
DR   AlphaFoldDB; Q9Z272; -.
DR   SMR; Q9Z272; -.
DR   BioGRID; 249809; 9.
DR   CORUM; Q9Z272; -.
DR   IntAct; Q9Z272; 5.
DR   MINT; Q9Z272; -.
DR   STRING; 10116.ENSRNOP00000073267; -.
DR   GlyGen; Q9Z272; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Z272; -.
DR   PhosphoSitePlus; Q9Z272; -.
DR   SwissPalm; Q9Z272; -.
DR   jPOST; Q9Z272; -.
DR   PaxDb; 10116-ENSRNOP00000052961; -.
DR   ABCD; Q9Z272; 1 sequenced antibody.
DR   Ensembl; ENSRNOT00055046345; ENSRNOP00055038020; ENSRNOG00055026761.
DR   Ensembl; ENSRNOT00060051210; ENSRNOP00060042604; ENSRNOG00060029464.
DR   Ensembl; ENSRNOT00065033521; ENSRNOP00065026813; ENSRNOG00065019852.
DR   GeneID; 83709; -.
DR   KEGG; rno:83709; -.
DR   AGR; RGD:69331; -.
DR   CTD; 28964; -.
DR   RGD; 69331; Git1.
DR   eggNOG; KOG0818; Eukaryota.
DR   InParanoid; Q9Z272; -.
DR   OrthoDB; 2877020at2759; -.
DR   PhylomeDB; Q9Z272; -.
DR   Reactome; R-RNO-3928664; Ephrin signaling.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013404; RAC2 GTPase cycle.
DR   Reactome; R-RNO-9013406; RHOQ GTPase cycle.
DR   Reactome; R-RNO-9013420; RHOU GTPase cycle.
DR   Reactome; R-RNO-9013424; RHOV GTPase cycle.
DR   EvolutionaryTrace; Q9Z272; -.
DR   PRO; PR:Q9Z272; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0044305; C:calyx of Held; ISO:RGD.
DR   GO; GO:0005813; C:centrosome; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; IDA:RGD.
DR   GO; GO:0005768; C:endosome; IDA:RGD.
DR   GO; GO:0060076; C:excitatory synapse; IDA:RGD.
DR   GO; GO:0005925; C:focal adhesion; TAS:RGD.
DR   GO; GO:0098982; C:GABA-ergic synapse; IDA:SynGO.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0030426; C:growth cone; IDA:RGD.
DR   GO; GO:0060077; C:inhibitory synapse; IDA:RGD.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0097431; C:mitotic spindle pole; ISS:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0014069; C:postsynaptic density; IEA:UniProtKB-SubCell.
DR   GO; GO:0098793; C:presynapse; ISO:RGD.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0043015; F:gamma-tubulin binding; ISS:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:RGD.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; IPI:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; ISO:RGD.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:RGD.
DR   GO; GO:0031267; F:small GTPase binding; IDA:RGD.
DR   GO; GO:0098879; F:structural constituent of postsynaptic specialization; IDA:SynGO.
DR   GO; GO:0007420; P:brain development; ISO:RGD.
DR   GO; GO:0045454; P:cell redox homeostasis; ISS:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IDA:RGD.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; IGI:MGI.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0001771; P:immunological synapse formation; IGI:MGI.
DR   GO; GO:0001957; P:intramembranous ossification; ISS:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0061743; P:motor learning; ISO:RGD.
DR   GO; GO:0032013; P:negative regulation of ARF protein signal transduction; IDA:RGD.
DR   GO; GO:0045820; P:negative regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0106015; P:negative regulation of inflammatory response to wounding; ISS:UniProtKB.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; ISS:UniProtKB.
DR   GO; GO:0048666; P:neuron development; ISO:RGD.
DR   GO; GO:0099645; P:neurotransmitter receptor localization to postsynaptic specialization membrane; IDA:SynGO.
DR   GO; GO:0090063; P:positive regulation of microtubule nucleation; ISS:UniProtKB.
DR   GO; GO:2000646; P:positive regulation of receptor catabolic process; IMP:RGD.
DR   GO; GO:0099171; P:presynaptic modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0032012; P:regulation of ARF protein signal transduction; IBA:GO_Central.
DR   GO; GO:0032465; P:regulation of cytokinesis; ISO:RGD.
DR   GO; GO:0008277; P:regulation of G protein-coupled receptor signaling pathway; IDA:RGD.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; ISO:RGD.
DR   GO; GO:0036465; P:synaptic vesicle recycling; IBA:GO_Central.
DR   CDD; cd08846; ArfGap_GIT1; 1.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR   Gene3D; 1.10.220.150; Arf GTPase activating protein; 1.
DR   Gene3D; 1.20.120.330; Nucleotidyltransferases domain 2; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR037278; ARFGAP/RecO.
DR   InterPro; IPR001164; ArfGAP_dom.
DR   InterPro; IPR038508; ArfGAP_dom_sf.
DR   InterPro; IPR047161; GIT-like.
DR   InterPro; IPR032352; GIT1/2_CC.
DR   InterPro; IPR022018; GIT1_C.
DR   InterPro; IPR013724; GIT_SHD.
DR   PANTHER; PTHR46097:SF1; ARF GTPASE-ACTIVATING PROTEIN GIT1; 1.
DR   PANTHER; PTHR46097; G PROTEIN-COUPLED RECEPTOR KINASE INTERACTING ARFGAP; 1.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF01412; ArfGap; 1.
DR   Pfam; PF12205; GIT1_C; 1.
DR   Pfam; PF16559; GIT_CC; 1.
DR   Pfam; PF08518; GIT_SHD; 2.
DR   PRINTS; PR00405; REVINTRACTNG.
DR   SMART; SM00248; ANK; 3.
DR   SMART; SM00105; ArfGap; 1.
DR   SMART; SM00555; GIT; 2.
DR   SUPFAM; SSF48403; Ankyrin repeat; 1.
DR   SUPFAM; SSF57863; ArfGap/RecO-like zinc finger; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 1.
DR   PROSITE; PS50115; ARFGAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ANK repeat; Cell junction; Cell projection; Coiled coil;
KW   Cytoplasm; Cytoskeleton; GTPase activation; Metal-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Synapse; Zinc; Zinc-finger.
FT   CHAIN           1..770
FT                   /note="ARF GTPase-activating protein GIT1"
FT                   /id="PRO_0000074202"
FT   DOMAIN          1..124
FT                   /note="Arf-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00288"
FT   REPEAT          132..161
FT                   /note="ANK 1"
FT   REPEAT          166..195
FT                   /note="ANK 2"
FT   REPEAT          199..228
FT                   /note="ANK 3"
FT   ZN_FING         11..34
FT                   /note="C4-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00288"
FT   REGION          1..124
FT                   /note="Interaction with gamma-tubulin and localization to
FT                   the centrosome"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   REGION          245..374
FT                   /note="Interaction with PCLO"
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   REGION          253..424
FT                   /note="Interaction with PTK2/FAK1"
FT                   /evidence="ECO:0000269|PubMed:10938112"
FT   REGION          254..376
FT                   /note="Interaction with ARHGEF7"
FT                   /evidence="ECO:0000269|PubMed:10938112"
FT   REGION          363..425
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          375..596
FT                   /note="Interaction with NCK2 and GRIN3A"
FT                   /evidence="ECO:0000269|PubMed:17310244,
FT                   ECO:0000269|PubMed:24297929"
FT   REGION          375..596
FT                   /note="Required for localization at synapses"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   REGION          420..475
FT                   /note="Interaction with MAPK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   REGION          429..629
FT                   /note="Interaction with IKBKG"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   REGION          574..615
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          646..770
FT                   /note="Interaction with PXN and TGFB1I1"
FT                   /evidence="ECO:0000269|PubMed:10938112,
FT                   ECO:0000269|PubMed:12153727"
FT   COILED          449..483
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:19136011"
FT   COMPBIAS        363..380
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        407..425
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        574..591
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         224
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         371
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         373
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         379
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         392
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         394
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         397
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         401
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         422
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         426
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         507
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         545
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         546
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68FF6"
FT   MOD_RES         554
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         563
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         570
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         601
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         605
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         610
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Y2X7"
FT   MOD_RES         639
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MUTAGEN         285
FT                   /note="F->A: Loss of interaction with FAK1, decreased
FT                   interaction with PCLO, no effect on interaction with
FT                   ARHGEF7."
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   MUTAGEN         288
FT                   /note="L->A: Loss of interaction with PCLO and FAK1, no
FT                   effect on interaction with ARHGEF7."
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   MUTAGEN         298
FT                   /note="R->A: Loss of interaction with FAK1, decreased
FT                   interaction with PCLO, no effect on interaction with
FT                   ARHGEF7."
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   MUTAGEN         299
FT                   /note="R->A: Loss of interaction with FAK1, decreased
FT                   interaction with PCLO, no effect on interaction with
FT                   ARHGEF7."
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   MUTAGEN         392
FT                   /note="Y->F: Loss of interaction with NCK2."
FT                   /evidence="ECO:0000269|PubMed:17310244"
FT   MUTAGEN         432..483
FT                   /note="Missing: Decreased homooligomerization and loss of
FT                   formation of a ternary complex between GIT1, ARHGEF7 and
FT                   PCLO. Does not affect ARHGEF7- and PCLO-binding to GIT1
FT                   monomer."
FT                   /evidence="ECO:0000269|PubMed:12473661"
FT   HELIX           432..481
FT                   /evidence="ECO:0007829|PDB:2W6A"
FT   STRAND          645..647
FT                   /evidence="ECO:0007829|PDB:2JX0"
FT   HELIX           651..673
FT                   /evidence="ECO:0007829|PDB:6IUH"
FT   HELIX           677..679
FT                   /evidence="ECO:0007829|PDB:6IUH"
FT   HELIX           680..695
FT                   /evidence="ECO:0007829|PDB:6IUH"
FT   STRAND          700..702
FT                   /evidence="ECO:0007829|PDB:2JX0"
FT   HELIX           705..725
FT                   /evidence="ECO:0007829|PDB:6IUH"
FT   HELIX           726..728
FT                   /evidence="ECO:0007829|PDB:6IUH"
FT   HELIX           739..766
FT                   /evidence="ECO:0007829|PDB:6IUH"
SQ   SEQUENCE   770 AA;  85231 MW;  797C8EB7FCB3F481 CRC64;
     MSRKGPRAEV CADCSAPDPG WASISRGVLV CDECCSVHRS LGRHISIVKH LRHSAWPPTL
     LQMVHTLASN GANSIWEHSL LDPAQVQSGR RKANPQDKVH PIKSEFIRAK YQMLAFVHKL
     PCRDDDGVTA KDLSKQLHSS VRTGNLETCL RLLSLGAQAN FFHPEKGTTP LHVAAKAGQT
     LQAELLVVYG ADPGSPDVNG RTPIDYARQA GHHELAERLV ECQYELTDRL AFYLCGRKPD
     HKNGHYIIPQ MADRSRQKCM SQSLDLSELA KAAKKKLQAL SNRLFEELAM DVYDEVDRRE
     NDAVWLATQN HSTLVTERSA VPFLPVNPEY SATRNQGRQK LARFNAREFA TLIIDILSEA
     KRRQQGKSLS SPTDNLELSA RNQSDLDDQH DYDSVASDED TDQEPLPSAG ATRNNRARSM
     DSSDLSDGAV TLQEYLELKK ALATSEAKVQ QLMKVNSSLS DELRKLQREI HKLQAENLQL
     RQPPGPVPVP SLPSERAEHT LMGPGGSTHR RDRQAFSMYE PGSALKPFGG APGDELATRL
     QPFHSTELED DAIYSVHVPA GLYRIRKGVS ASSVTFTPSS PLLSSSQEGS RHASKLSRHG
     SGAESDYENT QSGEPLLGLE GKRFLELSKE DELHAELESL DGDPDPGLPS TEDVILKTEQ
     VTKNIQELLR AAQEFKHDSF VPCSEKIHLA VTEMASLFPK RPALEPVRSS LRLLNASAYR
     LQSECRKTVP PEPGAPVDFQ LLTQQVIQCA YDIAKAAKQL VTITTREKKQ
//
